Clinical trials: Community Acquired Pneumonia (CAP)
Coccidioidomycosis, Pneumonia
An Observational Study to Assess the Prevalence and Outcomes of Primary Pulmonary Coccidioidomycosis in Persons Aged > / = 14 Years Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (SAnds-PPC)
This is an observational study in 750 individuals aged 14 years or older, diagnosed with Community Acquired Pneumonia (CAP) who meet all eligibility criteria in Coccidioides endemic regions.
- Trial name
- NCT03908632
- Where
- 6 sites in United States
- Volunteers
- 651 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Community-acquired Pneumonia
pedCAPNETZ - Community Acquired Pneumonia (CAP) in Childhood and Adolescence
Establishment of a study network and patient cohort for pediatric CAP
- Trial name
- pedCAPNETZ (NCT04047108)
- Where
- Germany
- Volunteers
- 1,000 people
- Sponsor
- Hannover Medical School
Community-acquired Pneumonia
Role of Multiplex PCR in CAP
1. role of multiplex PCR in early identifying bacteria in patients with lower respiratory tract infection. 2. effect of early starting targeted antibiotics on outcome
- Trial name
- NCT06097117
- Testing
- MultiplexPCR
- Volunteers
- 66 people
- Sponsor
- Assiut University
Bacterial Pneumonia
Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia
The purpose of the study is to determine if the antibiotic ceftaroline is safe and effective in the treatment of community-acquired pneumonia in adults.
- Trial name
- CAP (NCT00509106)
- Testing
- Ceftaroline fosamil for Injection, Ceftriaxone
- Where
- 134 sites in United States, Argentina and 13 more
- Volunteers
- 622 people
- Sponsor
- Forest Laboratories
Community Acquired Pneumonia
A Global Active Surveillance for Community Acquired Pneumonia
This study is an observational surveillance study to identify adults 50 years and older who present to a study healthcare facility with signs and symptoms of Community-Acquired Pneumonia.
- Trial name
- NCT00929721
- Testing
- Blood draw, Chest X-ray, urine specimen
- Where
- Poland
- Volunteers
- 5,172 people
- Sponsor
- Pfizer
Pneumonia
Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia (CAP)
The purpose of this study is to compare the efficacy of cethromycin to clarithromycin for the treatment of mild to moderate community-acquired pneumonia (CAP).
- Trial name
- NCT00336505
- Testing
- Cethromycin, Clarithromycin
- Where
- 3 sites in United States
- Volunteers
- 584 people
- Sponsor
- Advanced Life Sciences, Inc.
Acute Exacerbation of Chronic Bronchitis, Community-Acquired Pneumoniae
Comparison of Cefdinir and Cefdinir/Clavulanic Acid Combination in Adults
It is planned to compare the efficacy and safety of cefdinir and cefdinir/clavulanic acide treatments in acute exacerbation of chronic bronchitis (AECB) and community-acquired pneumoniae (CAP) patients.
- Trial name
- NCT03400735
- Testing
- Cefdinir/clavulanic acide 300/125 mg film-coated tablets, Cefdinir 300Mg Capsule
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Neutec Ar-Ge San ve Tic A.Ş
Pneumonia, Community-Acquired Infections
Helmet Continuous Positive Airway Pressure Versus Oxygen Venturi in Acute Respiratory Failure in CAP: CAPOVeRSO
The purpose of this study is to compare the efficacy of CPAP application by a helmet and O2 administration by a Venturi mask in terms of gas exchanges improvement in patients with acute respiratory failure due to…
- Conditions
- Pneumonia, Community-Acquired Infections, Respiratory Insufficiency, Acute Lung Injury
- Trial name
- CAPOVeRSO (NCT00603564)
- Testing
- Castar Starmed (CPAP) delivered by a helmet
- Where
- Italy
- Volunteers
- 47 people
- Sponsor
- University of Milan
Chronic Obstructive Pulmonary Disease, Community-acquired Pneumonia
A Pre-post Intervention Study Evaluating Home-based Management of Patients With COPD or CAP
Risk of rehospitalization within 30 days of discharge is higher than 20% in patients with chronic obstructive pulmonary disease (COPD) and up to 20% for patients with community acquired pneumonia (CAP).
- Trial name
- NCT05009485
- Testing
- Current Health platform
- Sponsor
- Current Health
Sepsis, Community Acquired Pneumonia (CAP)
OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis
OPT101-100-40 is a multicenter, randomized, placebo-controlled, multiple-ascending-dose, sequential-group, investigator- and participant-blinded, sponsor-unblinded, study of OPT101 vs placebo when administered for up to 4 days to…
- Trial name
- NCT06669403
- Testing
- OPT101
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Op-T LLC
Community Acquired Pneumonia, Severe
Ticagrelor in Severe Community Acquired Pneumonia
The purpose of this study is to determine if the drug ticagrelor will be an effective treatment for patients with severe community acquired pneumonia.
- Trial name
- TCAP (NCT01998399)
- Testing
- Ticagrelor
- Where
- 26 sites in United States
- Volunteers
- 25 people
- Sponsor
- Gordon Bernard
Community-acquired Pneumonia, SARS-CoV-2 -Associated Pneumonia
CX-4945 in Viral Community Acquired Pneumonia
This is a Phase II, multi-center, double-blind, randomized, interventional study in approximately 120 subjects to evaluate clinical benefit of CX-4945 in adult outpatients with SARS-CoV-2 and influenza viral infection-associated…
- Conditions
- Community-acquired Pneumonia, SARS-CoV-2 -Associated Pneumonia, Influenza With Pneumonia
- Trial name
- NCT06202521
- Testing
- CX-4945 (SARS-CoV-2 domain), CX-4945 (Influenza virus domain)
- Where
- 7 sites in Taiwan
- Volunteers
- 45 people
- Sponsor
- Senhwa Biosciences, Inc.
Pneumonia
A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics of BAYQ3939 in Patients With Bacterial Pneumonia
The main objective of this study is to investigate the safety, pharmacokinetics (PK) and the relationship between PK and pharmacodynamics (Minimum Inhibitory Concentration [MIC] and Mutant Prevention Concentration [MPC]) of…
- Trial name
- NCT01561794
- Testing
- Ciprofloxacin (Cipro, BAYQ3939)
- Where
- 20 sites in Japan
- Volunteers
- 44 people
- Sponsor
- Bayer
Community-Acquired Pneumonia (CAP)
How Does Medical Clown Intervention Affect the Length of Hospitalization in Children With Pneumonia
Background and Objectives: Community-acquired pneumonia (CAP) is a leading cause of hospitalization in children. The hospitalization duration depends on factors as child's well-being, vital signs, need for parenteral treatments…
- Trial name
- NCT06750029
- Testing
- Medical clown visits
- Where
- Israel
- Volunteers
- 51 people
- Sponsor
- Carmel Medical Center
Community-Acquired Pneumonia
Efficacy and Safety Trial to Assess Moxifloxacin in Treating Community-Acquired Pneumonia (CAP) With Aspiration Factors
The purpose of this study is to determine whether moxifloxacin in comparison to levofloxacin plus metronidazole are effective and safe in the treatment of community-acquired pneumonia with aspiration factors.
- Trial name
- NCT00752947
- Testing
- moxifloxacin, levofloxacin, metronidazole
- Where
- 2 sites in China
- Volunteers
- 186 people
- Sponsor
- Beijing Hospital
Antimicrobial Resistance (AMR)
NCCR AntiResist:: New Approaches to Combat Antibiotic-resistant Bacteria
This is an explorative, mono-center study including prospectively collected patient samples from the University Hospital of Basel.
- Trial name
- AntiResist (NCT05017766)
- Testing
- analysis of antimicrobial resistance
- Where
- Switzerland
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Pneumonia
Study Comparing the Clinical Efficacy and Health Outcomes of Outpatients With Mild to Moderate Community-Acquired Pneumonia (CAP) Treated With Either Telithromycin Once Daily for 7 Days, or Azithromycin Once Daily for 5 Days
A multinational, multicenter, randomized, double-blind, study in areas of high pneumococcal resistance comparing the clinical efficacy and health outcomes of outpatients with mild to moderate Community-Acquired Pneumonia (CAP)…
- Trial name
- COBRA II (NCT00237445)
- Testing
- telithromycin, azithromycin
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Sanofi
Respiratory Infection (for Example, Pneumonia, Bronchitis), Respiratory Infection Virus
Kinetics and Metabolism of Nicotinamide Provided as a Dietary Supplementation
The diet of patients with reduced tryptophan serum levels that are either hospitalized for acute respiratory infection or treated for chronic inflammatory diseases such as inflammatory bowel diseases (in- or outpatients) is…
- Conditions
- Respiratory Infection (for Example, Pneumonia, Bronchitis), Respiratory Infection Virus, Community Acquired Pneumonia (CAP), COPD Acute Exacerbation
- Trial name
- CICR-NAM_PK (NCT07156929)
- Testing
- Controlled-ileocolonic-release nicotinamide (CICR-NAM): 500 mg/d, Controlled-ileocolonic-release nicotinamide (CICR-NAM): 1000 mg/d
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- University Hospital Schleswig-Holstein
Pneumonia, Pneumococcal, Community-acquired Pneumonia
Quantitative Polymerase Chain Reaction for Improved Detection of Pneumococci in CAP "CAPTAIN"
The purpose of this study is to evaluate the added diagnostic value of a quantitative polymerase chain reaction targeting the lytA gene in detecting pneumococci in patients with community-acquired pneumonia.
- Trial name
- CAPTAIN (NCT03315403)
- Testing
- LytA targeted quantitative polymerase chain reaction (qPCR)
- Where
- 2 sites in Netherlands
- Volunteers
- 922 people, healthy volunteers welcome
- Sponsor
- Medical Center Alkmaar
Sepsis
CLARITHROMYCIN TO PREVENT SECONDARY INFECTIONS IN PATIENTS WITH SEPSIS FOLLOWING LOWER RESPIRATORY TRACT INFECTIONS: THE CLASSIFY TRIAL
The goal of this clinical trial is to assess whether clarithromycin, given as an adjunct to standard-of-care antibiotic therapy, can reduce the risk of new infections and secondary sepsis in adult patients hospitalized with…
- Trial name
- CLASSIFY (NCT07834346)
- Testing
- clarithromycin
- Where
- 19 sites in Greece
- Volunteers
- 252 people
- Sponsor
- Hellenic Institute for the Study of Sepsis